ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...

Chemoimmunotherapy extended PFS compared with chemotherapy for patients with extensive-stage small cell lung cancer and ECOG performance status of 2 or 3, according to retrospective study results. The ...

Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis. Mark Socinski, MD: Martin, we have seen ...

Performance status (PS) is a crucial assessment for research and clinical practice in lung cancer (LC), including its usage for the assessment of the suitability and toxicity of treatment or ...

In new research on the status of cancer disparities in the United States, American Cancer Society (ACS) scientists report higher cancer mortality rates among adults living in rural areas, certain ...